Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients

Mohamed A. Ismail1,2*, Marzia Vezzalini3, Hisham Morsi4, Ahmad Abujaber2, Ali Al Sayab2, Kodappully Siveen2, Mohamed A. Yassin5, Maria Monne6, Muthanna Samara7, Richard Cook1, Claudio Sorio3, Helmout Modjtahedi1 & Nader I. Al‑Dewik1,8,9*

Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down‑regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TPγ B9‑2) and RT‑qPCR, and BCR-ABL1 transcript by RT‑qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients.

Abbreviations
AF  Alexa fluro
AP  Accelerated phase
APC  Allophycocyanin
ANOVA  Analysis of variance
BC  Blast crisis phase
BD  Becton and Dickinson biosciences company

1School of Life Science, Pharmacy and Chemistry, Faculty of Science, Engineering and Computing, Kingston University London, London, United Kingdom. 2Interim Translational Research Institute (iTRI), Hamad Medical Corporation (HMC), Doha, Qatar. 3Department of Medicine, University of Verona, Verona, Italy. 4Quality of Life Unit, National Center for Cancer Care and Research, (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar. 5Department of Medical Oncology, National Centre for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar. 6Centro di Diagnostica Biomolecolare e Citogenetica Emato-Oncologica, "San Francesco" Hospital, Nuoro, Italy. 7Department of Psychology, Kingston University London, Penrhyn Road, Kingston upon Thames KT1 2EE, United Kingdom. 8Qatar Medical Genetic Center (QMG), Hamad General Hospital (HGH), and Interim Translational Research Institute (iTRI), Hamad Medical Corporation (HMC), P.O. BOX. 3050, Doha, Qatar. 9College of Health and Life Science (CHLS), Genomics and Precision Medicine, Hamad Bin Khalifa University (HBKU), Doha, Qatar. 10email: mhmd_arby@yahoo.com; naldewik@hamad.qa
Chronic myeloid leukemia (CML) accounts for 15–20% of all hematological malignancies amongst adults. BCR/ABL is the first oncprotein discovered in patients with CML and the first target for therapeutic intervention with small molecule tyrosine kinase inhibitors (TKIs) based drugs. To date, five different BCR-ABL TKIs (i.e., Imatinib Mesylate (IM), Nilotinib, Dasatinib, Ponatinib, and Bosutinib) have been approved by the United States Food and Drug Administration (FDA) for the treatment of patients with CML. However, primary or secondary resistance to treatment with TKIs occur in some patients with CML, highlighting the need for better understanding the mechanisms of resistance and identification of the predictive biomarkers for the response to treatment.

Protein Tyrosine Phosphatase Gamma (PTPRG) is a tumor suppressor and a member of a family of receptors tyrosine phosphatases. It has the ability to remove a phosphate group from the phosphorylated amino acid tyrosine that is present on its substrate protein, thus balancing the ABL1 tyrosine kinase activities. PTPRG is located on the short arm (3p14.2) of chromosome 3 and consists of 30 exons. It has an extracellular domain, a transmembrane domain, a carbonic anhydrase-homologous amino terminus followed by a fibronectin III domain, and two intracellular PTPase catalytic domains of which the only one is active.

Flow cytometry is a simple and robust technique employed in many laboratories for the diagnostic and research purposes. It can also be of potential value in the monitoring of CML patients and their response to therapeutic intervention. In a previous study, we described the production of a monoclonal antibody that recognizes the extracellular domain of PTPRG (TPγ B9-2) on CML cell lines and patients' samples. This is a unique antibody with a potential capacity for monitoring the PTPRG expression in CML patients.
In this study, using flow cytometry, we determined the expression levels of PTPRG amongst a sub-population of white blood cells in healthy individuals and CML patients at the time of diagnosis and following treatment with TKIs. We also compared the effect of TKIs on BCR-ABL1 and PTPRG transcripts via Reverse Transcriptase PCR (RT-qPCR).

Results

To our knowledge, mAb TPγ B9-2 is currently the only mAb for use in the detection of PTPRG protein by flow cytometry. Therefore, in this study, the changes in the expression level of PTPRG protein were determined in the WBCs of seven healthy individuals and 21 CML patients at the time of diagnosis and following treatment with BCR-ABL TKIs, using flow cytometry.

Characteristics of CML patients at the time of diagnosis, their responses to the treatment with TKIs and healthy control participants.

Table 1.  CML patient’s characteristics: gender, age, clinical phase, TKIs (BCR/ABL1 and PTPRG) at diagnosis stage and response to treatment.  *CML04 AP with additional chromosomal (t(9:22) (q34, q11.2); t(11; 14) (q23, q32) (30).  bCML13 CP with Tuberculosis.  cCML20 AP with double Ph +.  dCML14 patient lost to record myeloid lineage events at time of relapsed.

| Patients | Gender | Age (years) | Diagnosis | BCR-ABL1(IS) (%) | PTPRG (%) | Treatment | Final response |
|----------|--------|-------------|-----------|------------------|-----------|-----------|---------------|
| CML 01  | M      | 61          | CP        | 57               | 0.02      | Imatinib (400 mg) | Failed       |
| CML 02  | M      | 61          | CP        | 100              | 0.03      | Imatinib (400 mg) | Optimal     |
| CML 03  | F      | 33          | CP        | 100              | 0.02      | Nilotinib (300 mg) | Optimal     |
| CML 04  | M      | 46          | AP*       | 100              | 0.01      | Nilotinib (300 mg) | Optimal     |
| CML 05  | M      | 23          | CP        | 100              | 0.01      | Imatinib (400 mg) | Failed      |
| CML 06  | M      | 48          | CP        | 100              | 0.02      | Imatinib (400 mg) | Optimal     |
| CML 07  | M      | 43          | CP        | 100              | 0.02      | Imatinib (400 mg) | Failed      |
| CML 08  | M      | 36          | CP        | 100              | 0.01      | Imatinib (400 mg) | Failed      |
| CML 09  | M      | 48          | CP        | 100              | 0.02      | Imatinib (400 mg) | Failed      |
| CML 10  | M      | 45          | CP        | 100              | 0.02      | Imatinib (400 mg) | Failed      |
| CML 11  | M      | 26          | CP        | 100              | 0.01      | Imatinib (400 mg) | Failed      |
| CML 12  | F      | 28          | CP        | 100              | 0.01      | Nilotinib (300 mg) | Optimal     |
| CML 13  | M      | 40          | CP        | 100              | 0.01      | Imatinib (600 mg) | Optimal     |
| CML 14  | M      | 45          | CP        | 100              | 0.01      | Nilotinib (300 mg) | Failed      |
| CML 15  | M      | 26          | CP        | 100              | 0.01      | Imatinib (400 mg) | Failed      |
| CML 16  | M      | 40          | CP        | 100              | 0.01      | Imatinib (400 mg) | Failed      |
| CML 17  | M      | 33          | CP        | 89               | 0.02      | Nilotinib (300 mg) | Optimal     |
| CML 18  | M      | 34          | CP        | 100              | 0.02      | Nilotinib (300 mg) | Optimal     |
| CML 19  | M      | 32          | AP        | 100              | 0.01      | Nilotinib (300 mg) | Optimal     |
| CML 20  | M      | 65          | AP*       | 100              | 0.01      | Nilotinib (300 mg) | Failed      |
| CML 21  | M      | 40          | CP        | 100              | 0.01      | Nilotinib (300 mg) | Optimal     |

In this study, using flow cytometry, we determined the expression levels of PTPRG amongst a sub-population of white blood cells in healthy individuals and CML patients at the time of diagnosis and following treatment with TKIs. We also compared the effect of TKIs on BCR-ABL1 and PTPRG transcripts via Reverse Transcriptase PCR (RT-qPCR).

Presentation of results.  Figure 1 shows the sequence of results and analysis that were performed using two techniques at different time points (diagnosis and follow up) for different comparisons.

Expression of BCR-ABL1 and PTPRG mRNA in whole white blood cells using RT-qPCR.  The expression levels of BCR-ABL1 and PTPRG mRNA levels in CML patients at diagnosis and follow up were determined by RT-qPCR and the results are presented in Fig. 2. As the results of Cohen’s d coefficient analysis show, there was a “huge” and “large” effect size on BCR-ABL1 (Cohen’s d = 5.05) and PTPRG transcripts (Cohen’s d = 0.81) following treatment with TKIs. A significant difference was found in the mean levels of BCR-ABL1 mRNA at diagnosis and at follow up (WSRT p < 0.001, Fig. 2a) and PTPRG mRNA at diagnosis and at follow up (WSRT p < 0.001, Fig. 2b). In contrast to BCR-ABL1 mRNA, which had significantly higher levels at diagnosis...
compared to follow up, PTPRG mRNA expression levels were found to be significantly lower at diagnosis compared to follow up. There was also a moderate negative correlation between \( \text{BCR-ABL1} \) at diagnosis and \( \text{PTPRG} \) at follow up (\( r_{(21)} = -0.422, p = 0.028 \)).

Moreover, the \( \text{PTPRG} \) transcript was also assessed to compare between optimal and failed CML groups. The results showed that the optimal response group had significantly higher \( \text{PTPRG} \) expression during follow up (\( \text{WSRT } p < 0.0005 \)) compared to diagnosis time-point, while no significant difference was found amongst the failed group at diagnosis and during follow up (\( \text{WSRT } p = 0.312 \), Fig. 2c).

PTPRG expression levels on white blood sub-populations (WBCs) of Healthy individuals and CML patients at diagnosis using flow cytometry. Next, the expression levels of PTPRG protein were determined in the WBC sub-populations of healthy and CML patients using flow cytometry and the results are presented in Figs. 3 and 4. A significant difference was found in the expression levels of PTPRG between different WBC sub-population (neutrophils, monocytes, and lymphocytes) \( \chi^2 (3, 5) = 19.15, p < 0.0001 \). PTPRG protein expression levels were found to be higher on neutrophils and monocytes when compared to lymphocytes in both healthy individuals (Fig. 3a,b) and CML patients at diagnosis (Fig. 3c).

When comparing healthy individuals against CML patients, PTPRG protein expression levels were significantly higher on neutrophils \( U = 30, p < 0.002 \) and monocytes \( U = 24, p < 0.007 \) amongst healthy individuals in comparison to CML patients at diagnosis (Fig. 3d). A significant difference was also found in the expression level of PTPRG on neutrophils between the healthy, optimal and failed groups \( H = 14.94, df = 3, p = 0.001 \). The optimal response group had higher expression PTPRG in their neutrophils compared to the healthy group \( U = 3, p = 0.004 \), and the failed groups had higher expression of PTPRG than the healthy group \( U = 7, p = 0.004 \).

Expression levels of PTPRG protein on neutrophils and monocytes in optimal and failed groups at follow up determined by flow cytometry. The PTPRG expression level on WBCs was also re-assessed during the follow up for both optimal and failed CML groups. There was a significant difference between the expression of PTPRG on the neutrophils \( \chi^2 (2, 11) = 13.82, p = 0.001 \) and monocytes \( \chi^2 (2,
During the follow-up time points in the optimal response group. For the neutrophils, there were significant differences between 1st follow up (median: 3.68) and 2nd follow up (median: 4.8, Z = −2.93, p < 0.001) and 1st follow up and 3rd follow up (median: 4.9) (Z = −2.67, p < 0.001), but no significant differences between the 2nd and 3rd follow up (Z = −0.89, p = 0.37, Fig. 5a). However, for the monocytes there were only significant differences in its expression levels between 1st follow up (median: 3.5) and 3rd follow up (median: 4.5, Z = −2.05, p = 0.004, Fig. 5). There were no significant differences between the follow up time-points in relation to the expression of PTPRG on the lymphocytes in the optimal response group (χ² (2, 11) = 2, p = 0.6).

In the failed response group, there were significant differences in the PTPRG expression levels between 1st follow up (median: 3.1) and 2nd follow up (median: 4.0) (Z = −2.8, p < 0.005) and 1st and 3rd follow up (median: 4.5, Z = −2.6, p = 0.009), but no significant difference between 2nd and 3rd follow up (Z = −1.33, p = 0.19, Fig. 5b). For the monocytes, there were significant differences between only the 1st follow up (median: 3.8) and 3rd follow up (median: 4.6), (Z = −2.7, p = 0.027, Fig. 5). In contrast, there were no significant differences in the expression levels of PTPRG protein between the follow up time-points in the failed response group (χ² (2, 10) = 2, p = 0.8).

When PTPRG expression was compared on neutrophils of optimal and failed group, there was no significant difference in the 1st follow up (U = 39, p = 0.26). On the other hand, there were significant differences between the two response groups at the 2nd follow up (U = 25.5, p = 0.036) and the 3rd follow up (U = 28.0, p = 0.05) (Fig. 5c). No significant differences in the monocytes of the optimal and failed groups were found between the follow up time points (1st follow up (U = 46.0, p = 0.53), 2nd follow up (U = 49.5, p = 0.7) and 3rd follow up (U = 48.0, p = 0.62)) (Fig. 5f).

In CML patients, the impact of treatment (Nilotinib vs. Imatinib) on neutrophils’ PTPRG expression significantly differed over time (Nilotinib: χ² (3, 8) = 18.45, p = 0.001; Imatinib: χ² (3, 12) = 32.9, p = 0.001).
was a significant treatment effect between diagnosis and 1st follow up (only for Nilotinib treatment) ($U = 22, p = 0.047$), between diagnosis and 2nd follow up (both treatments), and between diagnosis and 3rd follow up (both treatments). On the other hand, only Imatinib treatment was significantly more effective at the 3rd follow up compared to the 1st follow up (Table 2B).

Figure 3. PTPRG protein expressions on sub-population of white blood cells of healthy individuals (H) and CML patients (ND). (a) Level of PTPRG expression on sub-population of white blood cells of (H). (Y-axis) refers to count numbers of peripheral blood cells recorded in each sub-population at flow cytometry acquisition. The expression of PTPRG was reported in Mean Fluorescent Intensity (MFI). (b) The mean of PTPRG expression (H) on both neutrophils (mean = 3.0), monocytes (mean = 2.8) was significantly higher when compared with lymphocytes (mean = 0.89). (c) The median of PTPRG expression (ND) on monocytes (median = 1.7); neutrophils (median = 1.5) was significantly higher when compared with lymphocytes (median = 1.14). (d) PTPRG expression on neutrophils and monocytes was significantly lower in CML (ND) patients in comparison with healthy individuals (H).
**PTPRG expression on myeloid progenitors within the optimal and failed groups.** After analysis of mature population (WBCs), we studied PTPRG expression in two subpopulations of progenitors’ cells, leukemic stem cell (LSCs) and hematopoietic stem cells (HSCs). The results show that there was no significant difference in PTPRG expression at the time of diagnosis ($U = 31, p = 0.183$), although the mean of PTPRG expression level on (LSC) (medium Glass’ Delta effect size: 0.52) was higher than HSC (small Glass’ Delta effect size: 0.17) (Table 3). Furthermore, the mean rank of PTPRG expression on LSC at the time of diagnosis in the failed group was significantly higher than the optimal group ($U = 12, p < 0.004$).

**Discussion**
In this study, for the first time we investigated the changes in the PTPRG protein level in CML patients at the State of Qatar determined by flow cytometry using a unique monoclonal antibody against the external domain of PRPRG. We confirmed that restoration levels of PTPRG were significantly greater during the follow-up period following treatment with BCR-ABL1 TKIs compared to the time of diagnosis (Fig. 4b). Moreover, stratification of CML patients’ response into optimal and failed treatment groups showed that the expression level of PTPRG to be significantly higher in the optimal response group when compared to the failed group, utilizing both q-PCR and flow cytometry techniques. Our results also confirmed our earlier findings using RQ PCR, in which 33 CML patients had been studied and the mRNA level of PTPRG was found to be significantly high in patient achieving Major Molecular Response (MMR), while this was not the case in non-responsive cases.

There is currently no clear associations between the expression of a biomarker at mRNA level and its translation at protein level and the link between the two parameters ranged from 40% up to 90% in other publications. On the contrary, other publications reported a low correlation between levels of mRNA and protein expression due to many factors including steady state, degradation, proteomics, and transcriptomics factors. In the current study, we investigated the expression levels of PTPRG at both the mRNA and protein levels in parallel. While we did not find any significant differences in the expression of PTPRG at the mRNA level in the failed group ($U = 0.312$) (Fig. 2c), there were significant differences in the PTPRG protein expression level on neutrophils population in CML of the optimally treated group (Fig. 5c). Our results showed the importance of studying the expression levels of various biomarkers at both mRNA and protein levels.

In this study, we found that the restoration of the PTPRG level to be significantly higher on the neutrophils population in the optimal response group, when compared to the failed group at two follow up points (2nd and 3rd follow up) (Fig. 5c). On the other hand, there was not a significant difference in the expression of PTPRG on the monocytes population between the optimal and the failed groups at any follow up point (Fig. 5f). Our data also showed that the restoration of PTPRG expression on neutrophils was drug-dependent as the expression of PTPRG was restored earlier with Nilotinib when compared to Imatinib Mesylate. This observation might reflect the superior potency of Nilotinib as BCR-ABL1 TKI, which was reported to be 20–50 times more potent than Imatinib, and its ability to achieve complete response superior compared to Imatinib Mesylate.

In another study, Naoto and his colleagues developed a fluorescence in situ hybridization (FISH) technique named “Neutrophil-FISH” that has the ability to classify CML cohort to responder and non-responder to Imatinib Mesylate. In the current study, we reported the ability of mAb TPγ B9-2 to record changes in expression of PTPRG on neutrophils by flow cytometry technique and consequently classify the CML patients in the same manner.

The restoration of PTPRG expression reached the level recorded in healthy individuals and this may be explained by the recovery of healthy hematopoiesis in these subjects due to that TKIs having a large impact on the PTPRG gene. On the other hand, there was still a significant difference between levels of PTPRG in healthy, optimally, and failed groups. This may be explained by overexpression of PTPRG to overcome the uncontrolled BCR-ABL1 kinase activity.

In relation to expression of PTPRG on myeloid lineage, our previous study have shown a low level of PTPRG expression in CML on myeloid lineage at the time of diagnosis. Interestingly, in this study, we found the mean PTPRG expression level to be higher in hematopoietic stem cells when compared to leukemic stem cells. The Glass’ Delta effect size equation showed a small effect size of level of PTPRG at LSCs, as compared to a medium effect size of the level of PTPRG on LSCs (Table 3). Additionally, the expression of PTPRG on LSCs was significantly higher in the failed group when compared to the optimal response. The result was matched with the fact that leukemic stem cells have a unique cell surface profile, which is different from that of hematopoietic cells.

Furthermore, LSCs had the ability to self-renewal, and LSCs had a signatory high expression of a gene, which is independently associated with adverse outcomes of treatment and could predict the prognosis of the disease.

A recent study documented that BCR-ABL1 transcripts maybe not transcribed by LSC of CML patients. Finally, primary resistance and acquired resistance to treatment with BCR-ABL1 TKIs can occur in some patients with CML. In Qatar, a significantly higher percentage of CML patients develop resistance to TKIs compared to the other parts of the world. This may be due to the fact that most studies in CML management were focused on one component (tyrosine kinases), while the other arm (tyrosine phosphatases) has not yet received equivalent attention.

In summary, in this study, we have shown that the expression of PTPRG, a tumor suppressor gene, is suppressed in CML patients and this can be restored following treatment with TKIs to levels observed in healthy controls. We have also shown that restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared with imatinib. Taken together, our results support that determination of PTPRG expression level by flow cytometry as a new biomarker of response to treatment with BCR-ABL1 TKIs is a useful tool for studying its role in tumor progression and predicting the response to therapeutic interventions and clinical management in patients with CML.
Figure 4. Gating strategies of flow cytometric analysis of PTPRG protein and its expression during the treatment plan. (a) Gating strategies of PTPRG expression on the sub-population of white blood cells. Neutrophils (red color) have an intermediate level of CD45 and high side-scattered light (SSC); Monocytes (blue color) have a slightly higher level of CD45 expression and intermediate SSC, while lymphocytes (green color) have the highest level of expression of CD45 but the lowest level of SSC. Doublets discrimination and exclusion of dead cells using 7-AAD staining (red rectangle) allow an easier identification of positively stained populations. In comparison the lower population was the target of part of the leukemic stem cell. (b) Neutrophils and Monocytes showed a low level of PTPRG expression at the time of diagnosis. PTPRG restored its expression, at least in part of the sub-population of white blood cells followed by TKIs therapy. Of note, lymphocytes remained at a low level acting as an internal control. Follow up time points F1, F2 and F3 were 3, 6, and 12 months of successful TKIs as per ELN timelines. The MFI values were obtained by calculating the ratio differences between the signals derived from the signal of mAB TPγ B9-2 and irrelevant mouse IgG1. (c) Gating strategy to identify leukemic CD34+CD38− stem cells. For myeloid progenitors and its sub-population, we targeted 15–20% upper and lower population of CD34 (red color) with CD38, with the upper population corresponding to the target of interest (hematopoietic stem cells). In comparison the lower population correspond to part of the leukemic stem cell.

Materials and methods

Patient recruitment, characteristics and sample collection. Participants. A total of 21 adult CML patients whom were regularly followed up and treated with Tyrosine Kinase Inhibitors (Imatinib and Nilotinib) in the National Center for Cancer Care & Research clinics were recruited into this study. Peripheral blood samples were collected in EDTA tubes, where 63 subsequent samples were collected according to the ELN treatment timepoints. Seven matched healthy individuals (H) with normal complete blood count (CBC) and who were negative for BCR-ABL1 translocation were included in this study.

Patients’ blood samples, procedure, and ethics. Informed consent was obtained from all participants. The study was approved by both the Ministry of Public Health (MOPH) and the Institutional Review Board (IRB) of Hamad Medical Corporation (HMC) (Qatar) (Project No. 11118/11) and Kingston University London’s ethical committee (UK). This study adhered to the World Medical Association’s Declaration of Helsinki (1964–2008) for ethical human, research including confidentiality, privacy, and data management.

Blood samples were collected from newly diagnosed patients (ND) at day zero and before starting any tyrosine kinase inhibitor (TKI) or Hydroxyurea treatment. For failed/relapsed patients (F), blood samples were collected at the time of failure. The CML patients’ response to treatment was assessed based on the hematologic, cytogenetic, and molecular responses according to the European LeukemiaNet (ELN; 2013). The absence of one of the following was considered as treatment failure: abnormal complete blood count and/or Ph+ > 95% by 3 months, BCR-ABL1 > 10% and/or Ph+ > 35% by 6 months, or BCR-ABL1 > 1% and/or Ph+ > 0 by 12 months treatment36. The Optimal response group (R) was defined as achieving hematological, molecular, and cytogenetic remission within the time points of ELN guidelines.

Determination of PTPRG and BCR-ABL1 transcripts by RT-qPCR. A RT-qPCR was carried out to measure the mean levels of mRNA of PTPRG and BCR-ABL1 at 3, 6 and 12 months. Plasmids carrying PTPRG full length and BCR-ABL1 were utilized to standardize the number of copies measured by PCR as previously described47,36,37,38. Isolated white blood cells (2 × 106) were diluted into 200 μl phosphate-buffered saline (PBS1×) and transferred to FACS tubes (two tubes for isotope and PTPRG expression). The FACS tubes were placed on ice, and 5 μl CD45 primary antibody (Becton Dickinson international company (BD)-PE-CY7 anti-Human mouse Catalog No. 557748), 5 μl of CD34 antibody (BD-BV421 mouse anti-Human Catalog No. 562577), and 20 μl CD38 antibody (BD-APC labeled anti-Human Catalog No. 555462) were added and incubated in the dark for 20 min at 4 °C according to supplier’s recommendations. After washing, 20 μl of mouse IgG1-AP 488 antibody (BD-mouse IgG1-AF 488 Catalog No. 557782) and 1 μl of TPγ B9-2-AF488 antibody (1 μg) were added and incubated in the dark for 40 min then washed twice with cold PBS at 200 × g for 5 min at 4 °C. The samples were then analyzed by flow cytometry (BD LSR FORTESSA cell analyzer), where 500,000–1,000,000 numbers of events were targeted at acquisition records.

Flow cytometry. Isolated white blood cells (2 × 106) were diluted into 200 μl phosphate-buffered saline (PBS1×) and transferred to FACS tubes (two tubes for isotope and PTPRG expression). The FACS tubes were placed on ice, and 5 μl CD45 primary antibody (Becton Dickinson international company (BD)-PE-CY7 anti-Human mouse Catalog No. 557748), 5 μl of CD34 antibody (BD-BV421 mouse anti-Human Catalog No. 562577), and 20 μl CD38 antibody (BD-APC labeled anti-Human Catalog No. 555462) were added and incubated in the dark for 20 min at 4 °C according to supplier’s recommendations. After washing, 20 μl of mouse IgG1-AP 488 antibody (BD-mouse IgG1-AF 488 Catalog No. 557782) and 1 μl of TPγ B9-2-AF488 antibody (1 μg) were added and incubated in the dark for 40 min then washed twice with cold PBS at 200 × g for 5 min at 4 °C. The samples were then analyzed by flow cytometry (BD LSR FORTESSA cell analyzer), where 500,000–1,000,000 numbers of events were targeted at acquisition records.

Flow cytometry was performed on peripheral blood cells (PBCs) to characterize the expression of PTPRG on lymphocytes, monocytes, and neutrophils (LMN). The gating strategy of the flow cytometry experiment aimed at monitoring PTPRG expression in the major populations represented by neutrophils, monocytes and lymphocytes at diagnosis and during the follow up phase of TKIs treatment (Fig. 4a,b). L,M,N were gated with CD45 and side-scattered light (SSC). Neutrophils were characterized by intermediate CD45 and high SSC. Monocytes were characterized by higher CD45 expression and intermediate SSC, while lymphocytes have the highest expression of CD45 and the lowest level of SSC. Additionally, we targeted the level of PTPRG on myeloid lineages via the CD34 antibody and their sub-populations (CD34+/CD38−), CD34+/CD38+ (Dim) targeted leukemic stem cells (LSCs), while CD34+/CD38+ (bright) targeted hematopoietic stem cells (HSCs). The expression of PTPRG was reported in Mean Fluorescent Intensity (MFI) that represents the difference in expression between Target of Interest (TOI) and an isotype control.
Statistical analysis. All statistical tests were performed using SPSS v26. Changes in mRNA levels of (BCR-ABL1 & PTPRG) over timeline were analyzed with the Wilcoxon matched pairs signed ranks test (WSRT). The effect size of TKIs was reported and assessed on both genes (BCR-ABL1 & PTPRG) via the Cohen's d coefficient for which d = 0.2 was considered a 'small' effect size, 0.5 a 'medium' effect size, 0.8 a 'large' effect size and 2.0 a 'huge' effect size.
a “huge” effect size.$^{39,40}$ Additionally, a Spearman’s rank-order correlation was run to determine the relationship between the two genes. The distribution of the data was tested for normality with the Shapiro–Wilk test (W), and Skewness and normally distributed data was tested by the One-way Analysis Of Variance (ANOVA) and Dunnett’s multiple comparison tests. Non-normally distributed data was tested by Friedman and Dunnett’s multiple comparison tests. On the other hand, the Mann Whitney test was performed to analyze the difference between normally and non-normally distributed data. Changes in expression of PTPRG in CML patients over timeline were analyzed with Friedman and Wilcoxon signed ranks (WSRT) tests and a pairwise comparison with Hodges–Lehmann estimator. Finally, Kruskal–Wallis, along with Mann Whitney tests, were employed to examine the changes of PTPRG among healthy (H), optimally (R), and failed (F) groups.

Consent for publication. Consent for publication was obtained through ethics approval and consent to participate.

Data availability This is a research article, and all data generated or analyzed during this study are included in this published article. Please contact the corresponding author for data and material requests. Monoclonal Antibody for Diagnosing Chronic Myeloid Leukemia Patent Hamad Medical Corporation sponsored the patent process of the antibody and assignee: Qatar foundation. Provisional US patent application number: US62373322.

Received: 20 September 2020; Accepted: 22 March 2021
Published online: 23 April 2021

References
1. Soverini, S. et al. Best practices in chronic myeloid leukemia monitoring and management. Oncologist 21(5), 626–633 (2016).
2. García-Gutiérrez, V. & Hernandez-Boluda, J. C. Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety. Front. Oncol. 9, 603 (2019).
3. Gover-Proaktor, A. et al. Protein tyrosine phosphatase receptor gamma (PTPRG) is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 70(21), 8896–8906 (2010).
4. Patel, A. B., O’Hare, T. & Deininger, M. W. Identification of a carbonyl anhydride-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases. Mol. Cell Biol. 13(3), 1497–1506 (1993).
5. Barnea, G. et al. Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC (3;8) chromosome translocation. Genomics 32(2), 225–235 (1996).
6. Tonks, N. K. Protein tyrosine phosphatases: From genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7(11), 833–846 (2006).
7. Castara, K. et al. Identification of a novel leucocyte marker highly expressed by CD34 positive chronic myeloid leukemia patients studied by next generation sequencing (NGS): A pilot study in patients from the State of Qatar and Italy. Blood 128(22), 5427 (2016).
8. Ishmail, M. A. et al. Alteration DNA methylation of PTPRgamma as one possible mechanism of its under-expression in CML patients in the State of Qatar. Mol. Genet. Genom. Med. 8, e1319. https://doi.org/10.1002/mgg3.1319 (2020).
9. Orfao, A. et al. Flow cytometry in the diagnosis of cancer. Scand. J. Clin. Lab. Invest. Suppl. 221, 145–152 (1995).
10. Baccarini, M. et al. Antipsychotic drugs differentially affect mRNA expression of genes encoding the neuregulin 1-downstream ErbB4-P13K pathway. Pharmacology 98(1–2), 1–12 (2016).
11. Wu, H. & Tuller, T. Strong association between mRNA folding strength and protein abundance in S. cerevisiae. EMBO Rep. 13(3), 272 (2012).
12. Karbownik, M. S. et al. Antipsychotic drugs differentially affect mRNA expression of genes encoding the neuregulin 1-downstream ErbB4-P13K pathway. Pharmacology 98(1–2), 1–12 (2016).
13. Kumar, D. et al. Integrating transcriptome and proteome profiling: Strategies and applications. Proteomics 16(19), 2533–2544 (2016).
14. Lipps, H. P. & Hartmann, J. T. 45—Cytostatic and cytotoxic drugs. Side Effects Drugs Annu. 30, 520–532 (2008).
15. Takahashi, N. et al. Relevance in situ hybridization monitoring of BCR-ABL–positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. Int. J. Hematol. 81(3), 235–241 (2005).
16. Thilen, N. et al. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clin. Cancer Res. 22(16), 4030–4038 (2016).
17. Heidel, F. H., Mar, B. G. & Armstrong, S. A. Self-renewal related signaling in myeloid leukemia stem cells. Int. J. Hematol. 94(2), 109 (2011).
18. Gentles, A. J. et al. A leucemic stem cell gene expression signature is associated with clinical outcomes in acute myeloid leukemia. JAMA Intern. Med. 304(24), 2706 (2011).
30. Houshmand, M. et al. Chronic myeloid leukemia stem cells. *Leukemia* **33**(7), 1542–1556 (2019).
31. Apperley, J. F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. *Lancet Oncol.* **8**(11), 1018–1029 (2007).
32. Al-Dewik, N. I. et al. Studying the impact of presence of alpha acid glycoprotein and protein glycoprotein in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. *Biomark. Cancer* **7**, 63–67 (2015).
33. Baccarani, M., Rosti, G. & Soverini, S. Chronic myeloid leukemia: The concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. *Leukemia* **33**(10), 2358–2364 (2019).
34. Miliokovic, D. & Apperley, J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. *Clin. Cancer Res.* **15**(24), 7519–7527 (2009).
35. Al-Dewik, N. I. et al. Molecular monitoring of patients with chronic myeloid leukemia (CML) in the State of Qatar: Optimization of techniques and response to imatinib. *QScience Connect* **2014**(1), 24 (2014).
36. Baccarani, M. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood* **122**(6), 872–884 (2013).
37. Al-Dewik, N. I. et al. Is Adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar?. *Clin. Med. Insights. Oncol.* **10**, 95 (2016).
38. Al-Dewik, N. I. et al. Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. *QScience Connect* **2014**(1), 13 (2014).
39. Jacon, C. *Statistical Power Analysis for the Behavioral Sciences* (Routledge Academic-New York, 1998).
40. Sawilowsky, S.S. New effect size rules of thumb. *J. Mod. Appl. Stat. Meth.* **82**(2), 597–599 (2009).

**Acknowledgements**
This study was made possible by NPRP Grants (4-157-3-052) from the Qatar National Research Fund (a member of the Qatar Foundation). The statements made herein are solely the responsibility of the authors. The authors want to thank their respective institutions for their continued support. The publication of this article is funded by the Qatar National Library, Doha, Qatar.

**Author contributions**
M.I. and M.V. designed the experiment. M.I. and K.S. run the experiment. M.I., M.S., M.V., A.A. and N.D. designed and performed the statistical analysis. M.I., M.Y. and N.D. led patients recruitment. M.I., M.S., Hi.M., A.S., M.V., M.M., R.C., C.S., H.M., and N.D. conceptual work, framework, draft write-up and editing. All authors read and approved the final manuscript.

**Funding**
Open access funding provided by the Qatar National Library.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to M.A.I. or N.I.A.-D.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

| Open Access | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| © The Author(s) 2021 |